

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 336 014 B1**

(12)

**EUROPEAN PATENT SPECIFICATION**(45) Date of publication of patent specification: **24.06.92** (51) Int. Cl.<sup>5</sup>: **A61K 9/18, A61K 9/22**(21) Application number: **88120153.7**(22) Date of filing: **02.12.88**(54) **Pharmaceutical compositions with controlled release, and a method for their preparation.**(30) Priority: **08.04.88 IT 2014588**(43) Date of publication of application:  
**11.10.89 Bulletin 89/41**(45) Publication of the grant of the patent:  
**24.06.92 Bulletin 92/26**(84) Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**(56) References cited:  
**EP-A- 0 240 169**  
**US-A- 3 923 969**  
**US-A- 4 013 785**

**CHEMICAL ABSTRACTS**, vol. 94, no. 4, January 1981, page 306, abstract no. 20347n, Columbus, Ohio, US; K. UNGER et al.: "Incorporation of drugs in polycondensates of polyethoxysiloxane for mediating release of the active substance. I. Basis of the process and characterization of the pharmaceutical carrier (part 1)", & PHARM. IND. 1980, 42(10), 1027-30

**CHEMICAL ABSTRACTS**, vol. 81, no. 12, 23rd September 1974, page 335, abstract no. 68486r, Columbus, Ohio, US; H. RUPPRECHT

et al.: "Effect of pore structure of silica on the availability of drugs", & PHARM. IND. 1974, 36(4), 260-3

(73) Proprietor: **VECTORPHARMA INTERNATIONAL S.p.A.**  
**Corso Italia, 31**  
**I-34122 Trieste(IT)**

(72) Inventor: **Lovrecich, Mara Lucia**  
**Via dei Moreri, 23**  
**I-34100 Trieste(IT)**

(74) Representative: **Gervasi, Gemma, Dr. et al**  
**Studio Brevetti e Marchi NOTARBARTOLO & GERVASI 33, Viale Bianca Maria**  
**I-20122 Milano(IT)**

**EP 0 336 014 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

**Description**Field of the invention

5 This invention relates to pharmaceutical compositions with controlled release in which the active substance is incorporated in a microporous support.

Prior art

10 It is known to use microporous supports for incorporating active substances of pharmaceutical type to improve their useful properties.

For example, in order to increase the release rate of poorly soluble medicaments it has been proposed to incorporate them in a porous material either operating with a solution of said medicaments (European Patent Application 0163178) or operating by dry grinding (European Patent Application 0129893). An  
15 increase of the release rate is also obtained by tableting n-acetyl-p-aminophenol and fumed silicon dioxide (USP 4.013.785).

Again, various authors [DE 3230736, DE 2163034, Us 3923969, EP-A-0240169, Rupprecht H. et al., Colloid Polym. Sci. (1977) 255-3, pp.276-84] have suggested the use of porous silicas or zeolites or pillared clays to obtain prolonged release of the medicament by utilizing the dimensions and shape of the pores or  
20 the properties of the medicament adsorption on the silica surface.

Another process in which drugs are incorporated in porous SiO<sub>2</sub> by hydrolitic polycondensation of polyethoxysiloxane-drug dispersions is reported in Chem. Abs. 94 (1981), 20347n and again a study on the effect of pore structure of silica on the availability of drugs is reported in Chem. Abs. 81 (1974), 68486r.

In all the stated methods, the medicament is present either in the amorphous state or as microcrystals  
25 (dimensional range of the order of micrometers).

Summary of the invention

In the present invention the medicament is structured in crystalline form with crystals having a size of  
30 the order of nanometres.

This dispersion of the product as nanocrystals enables the chemical and physical stability of the medicament to be maintained and results in a sharp improvement in the biopharmaceutical properties of the system.

The present invention relates to pharmaceutical compositions and to the method for their preparation.

35 Said pharmaceutical compositions comprise a microporous support and an active substance incorporated therein and are characterised in that said active substance is distributed in the support pores as nanocrystals, said microporous support having pores of average diameter between 5 and 150 nm, a specific surface of between 30 and 600 m<sup>2</sup>/g, a particle diameter of less than 200 micrometers (microns) and the content of said active substance being between 4 and 60% by weight.

40 Said method is characterised by adding a microporous support to a solution of the active substance, stirring at ambient temperature for at least 70 hours and slowly evaporating the solvent under reduced pressure.

Detailed description of the invention

45 The pharmaceutical compositions according to the invention are prepared by the following method and have the characteristics stated hereinafter.

A solution of the active substance is prepared, a microporous support is added to this solution and the mixture obtained is kept stirring at ambient temperature for a prolonged time, at least 70 hours and  
50 preferably between 90 and 100 hours. After this treatment the solvent is evaporated slowly.

If the stirring time is less than 70 hours the desired active substance release characteristics are not obtained, whereas if the time is extended beyond 100 hours the improvement is negligible.

Preferred active substances for the compositions according to the invention are those of low water-solubility, which are released from said compositions at a higher rate than the pure substance. These  
55 substances are represented in numerous groups of medicaments such as in anti-hypertensives, anti-inflammatories, anti-anxiety agents, antidepressives, corticosteroids and antibactericides.

Particularly important examples of these substances are diazepam, digoxin, griseofulvin, methylhydroxypregesterone acetate, nifedipine, megestrol acetate, haloperidol, nicardipine, diltiazem and etoposide.

The solvents usable for the active substances are water, organic solvents, oils and molten semisolids, of which those preferred are chloroform, acetone, dichloroethane and ethyl alcohol. The solvent choice is made on the basis of the characteristics required for the composition.

Any substance compatible with the medicament can be used as the microporous support, for example silicas, silicates, zeolites, aluminas, activated carbons and microporous polymer substances.

The microporous supports must have an average pore diameter of between 5 and 150 nm and preferably between 7 and 110 nm, with a specific surface of between 30 and 600 m<sup>2</sup>/g and a particle diameter of less than 200 μm.

The active substance concentration in the solution depends on the solvent used and is preferably close to the saturation concentration. For example using chloroform, the concentration is between 2 and 40 g/l and preferably between 30 and 35 g/l, and the quantity of microporous support added is between 3 and 500 grams per litre of solution and preferably between 50 and 250 grams per litre of solution. After stirring the suspension, the solvent is removed by slow evaporation at a temperature of 10-20 °C less than the solution boiling point and at a pressure of between 500 and 760 mmHg (66.500 - 101.000 Pa).

The solid material obtained is disintegrated until a powder is obtained with a particle size of less than 200 micrometers (microns) and is heated in an oven at 20-30 °C under vacuum to remove the solvent traces.

In the composition obtained in this manner the active substance has nanocrystal dimensions with a diameter of between 3 and 100 nm, and a melting point less than that of the same solid of coarser dimensions.

The pharmaceutical compositions according to the invention have the following advantages over compositions obtained by known methods:

a) improved biopharmaceutical properties of the medicament due to its increased solubility which is related to the reduction in crystal dimensions by the known Kelvin equation:

$$\frac{S^*}{S^\circ} = \exp\left(\frac{2\gamma v}{RT r^*}\right)$$

where S\* is the solubility of finely divided crystals of radius r\*, S° is the solubility of crystals of the same solid but of coarse dimensions, γ is the solid/liquid interfacial tension, v is the molar volume of the solid, R is the universal gas constant and T is the absolute temperature;

b) in parallel with the lowering of the melting point of the medicament there are also considerable modifications in the rate of release of the medicament, which is more prolonged and controlled (release mechanism of zero order);

c) compared with systems containing the medicament in amorphous form, the compositions according to the invention containing the crystalline medicament with a lowered melting point not only have improved dissolving characteristics but also have increased chemical and physical stability. In this respect it is well known that amorphous products tend to crystallize with time, with resultant deterioration in their passage into solution.

The compositions according to the present invention can be used for preparing capsules, pharmaceutical forms for topical use, suppositories, tablets and transdermal films, and can contain the conventional excipients such as binding agents, fillers, lubricants, disintegrating agents, wetting agents, flavourings and colorants. For example they can contain substances such as gelatin, sorbitol, lactose, starch, magnesium stearate and sodium lauryl sulphate.

The following examples of the preparation and characteristics of the compositions according to the invention are given by way of illustration.

#### EXAMPLE 1

A solution of griseofulvin in chloroform and a solution of methylhydroxyprogesterone acetate (MHPA) in chloroform were prepared with a concentration of 35 g/l and 150 g/l respectively. 50 g of microporous silica gel with average pore radius 3.3 nm, specific surface 497.6 m<sup>2</sup>/g and particle size between 8 and 200 microns were added to 1 litre of griseofulvin solution and to 200 ml of MHPA solution.

In each case, the suspension obtained was kept stirring at ambient temperature for 96 hours. The solvent was then removed by evaporation at a temperature of 45 °C and a pressure of 700 mmHg (93.100 Pa) in a rotary evaporator until a product of powder form was obtained. This product was disintegrated to a

## EP 0 336 014 B1

particle size of between 8 and 200  $\mu\text{m}$  (microns) and heated in an oven to 30 °C under vacuum for 12 hours to eliminate all solvent traces.

The product obtained was subjected to the active substance release test using the USP XX paddle method under sink conditions, with 900 ml of buffer solution of pH 7.5 for the griseofulvin and of pH 5.5 for the MHPA, at 37 °C and at 150 r.p.m.

The product was also subjected to differential thermal analysis (D.S.C.) to determine its melting point and crystal size.

The thermal and dimensional characteristics of the two preparations are given in the following table:

	melting point ( ° C)	- $\Delta T$ on original medicament ( ° C)	Crystal diameter (nm)
Preparation with griseofulvin	123	96.8	4.0
Preparation with MHPA	113.5	92.6	5.2

The results of the dissolving test are given in the following table:

Time (minutes)	a) griseofulvin in solution ( $\mu\text{g/ml}$ )	b) MHPA in solution ( $\mu\text{g/ml}$ )
30	1.45	0.12
60	2.10	0.17
90	2.75	0.22
120	3.25	0.26

### EXAMPLE 2 (comparison)

Example 1 was repeated but with the difference that the suspension of microporous silica in the solution of active substance was kept stirring for 24 hours.

The thermal and dimensional characteristics of the two products are given in the following table:

	melting point ( ° C)	- $\Delta T$ on original medicament ( ° C)	Crystal diameter (nm)
Preparation with griseofulvin	206.2	13.6	30.0
Preparation with MHPA	198.5	7.6	40.0

The results of the active substance release test are given in the following table:

Time (minutes)	a) griseofulvin in solution ( $\mu\text{g/ml}$ )	b) MHPA in solution ( $\mu\text{g/ml}$ )
30	1.60	0.13
60	2.50	0.20
90	3.61	0.29
120	4.55	0.37

### EXAMPLE 3

Example 1 was repeated but with the difference that a microporous silica was used having an average pore radius of 7.7 nm.

The thermal and dimensional characteristics of the medicament crystals contained in the two products are given in the following table:

**EP 0 336 014 B1**

	melting point (° C)	- ΔT on original medicament (° C)	Crystal diameter (nm)
Preparation with griseofulvin	184.8	35.0	10.8
Preparation with MHPA	169.9	36.2	15.1

The results of the active substance release test are given in the following table:

Time (minutes)	a) griseofulvin in solution (μg/ml)	b) MHPA in solution (μg/ml)
30	1.45	0.12
60	2.10	0.17
90	2.75	0.22
120	3.25	0.26

**EXAMPLE 4 (comparison)**

Example 3 was repeated but with the difference that the suspension of microporous silica in the solution of active substance was kept stirring for 24 hours.

The thermal and dimensional characteristics of the medicament crystals contained in the two products are given in the following table:

	melting point (° C)	- ΔT on original medicament (° C)	Crystal diameter (nm)
Preparation with griseofulvin	206.2	13.6	30.0
Preparation with MHPA	198.5	7.6	40.0

The results of the active substance release test are given in the following table:

Time (minutes)	a) griseofulvin in solution (μg/ml)	b) MHPA in solution (μg/ml)
30	2.75	0.22
60	4.30	0.35
90	5.25	0.42
120	5.70	0.46

**EXAMPLE 5**

35 g of microporous silica gel with an average pore radius of 7.7 nm were added to 1 litre of a solution of griseofulvin in acetone at a concentration of 25 g/l. The suspension obtained was kept stirring at ambient temperature for 96 hours and the solvent was then removed by evaporation at 35 ° C and a pressure of 600 mmHg (79.800 Pa) in a rotary evaporator until a product of powder form was obtained.

This product was disintegrated to a particle size of between 8 and 200 micrometers (microns) and left under vacuum at ambient temperature for 12 hours to eliminate solvent traces.

The product obtained is in the form of crystals with a melting point of 203.5 ° C and a size of 25 nm. The results of the active substance release test are given in the following table:

Time (minutes)	griseofulvin in solution ( $\mu\text{g/ml}$ )
30	2.00
60	3.30
90	4.35
120	5.28

#### EXAMPLE 6

70 g of microporous silica gel with an average pore radius of 7.7 nm were added to 1 litre of a solution of griseofulvin in 1,2-dichloroethane at a concentration of 50 g/l. The suspension obtained was kept stirring at ambient temperature for 96 hours and the solvent was then removed by evaporation at 60°C and a pressure of 500 mmHg (66.500 Pa) in a rotary evaporator until a product of powder form was obtained.

This product was disintegrated to a particle size of between 8 and 200  $\mu\text{m}$  (microns) and left under vacuum at ambient temperature for 12 hours to eliminate solvent traces.

The product obtained is in the form of crystals with a melting point of 219.8°C (same melting point as original medicament) and a size of the order of micrometers (microns).

The results of the active substance release test are given in the following table:

Time (minutes)	griseofulvin in solution ( $\mu\text{g/ml}$ )
30	1.60
60	2.15
90	2.50
120	2.70

#### Claims

**Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Pharmaceutical compositions with controlled release comprising a microporous support containing the active substance in incorporated form, wherein said microporous support is chosen from the group of substances comprising silica, silicates, zeolites, alumina, activated carbon and microporous polymer substances having pores of average diameter between 5 and 150 nm, a specific surface of between 30 and 600  $\text{m}^2/\text{g}$  and a particle diameter of less than 200 micrometers, characterised in that said active substance is distributed within the support pores in crystalline form with a melting point less than that of the original medicament.
2. Compositions as claimed in claim 1, characterised in that the content of said active substance is between 4 and 60% by weight.
3. Compositions as claimed in claim 1, characterised in that said active substance is diazepam, digoxin, griseofulvin, methylhydroxyprogesterone acetate, nifedipine, megestrol acetate, haloperidol, nicardipine, diltiazem or etoposide.
4. A method for preparing pharmaceutical compositions with controlled release comprising a microporous support containing the active substance in incorporated form, wherein said microporous support is chosen from the group of substances comprising silica, silicates, zeolites, alumina, activated carbon and microporous polymer substances having pores of average diameter between 5 and 150 nm, a specific surface of between 30 and 600  $\text{m}^2/\text{g}$  and a particle diameter of less than 200 micrometers and said active substance is chosen from the group comprising diazepam, digoxin, griseofulvin, methylhydroxyprogesterone acetate, nifedipine, megestrol acetate, haloperidol, nicardipine, diltiazem and etoposide, characterised by adding said microporous support to a solution of the active substance, stirring at

ambient temperature for 90-100 hours, then slowly evaporating the solvent at a temperature of 10-20 ° C less than the solution boiling point and a pressure of between 500 and 760 mmHg (66.500 - 101.000 pa).

- 5 5. A method as claimed in claim 4, characterised in that the solvent for said solution of the active substance is chosen from the group comprising water, chloroform, acetone, dichloroethane and ethyl alcohol.
- 10 6. A method as claimed in claim 4, characterised in that, when the active substance is griseofulvine and the solvent is chloroform or acetone, the active substance concentration in said solution is between 2 and 40 g/l.
7. A method as claimed in claim 4, characterised in that the quantity of said microporous support added to said solution is between 3 and 500 grams per litre of solution.
- 15 8. The use of pharmaceutical compositions claimed in claim 1 for preparing capsules, tablets, transdermal films, pharmaceutical forms for topical use and suppositories.

#### Claims for the following Contracting States : ES, GR

- 20 1. A method for preparing pharmaceutical compositions with controlled release comprising a microporous support containing the active substance in incorporated form, wherein said microporous support is chosen from the group of substances comprising silica, silicates, zeolites, alumina, activated carbon and microporous polymer substances having pores of average diameter between 5 and 150 nm, a  
25 specific surface of between 30 and 600 m<sup>2</sup>/g and a particle diameter of less than 200 micrometers and said active substance is chosen from the group comprising diazepam, digoxin, griseofulvin, methyl-hydroxyprogesterone acetate, nifedipine, megestrol acetate, haloperidol, nicardipine, diltiazem and etoposide, characterised by adding said microporous support to a solution of the active substance,  
30 stirring at ambient temperature for 90-100 hours, then slowly evaporating the solvent at a temperature of 10-20 ° C less than the solution boiling point and a pressure of between 500 and 760 mmHg (66.500 - 101.000 pa).
2. A method as claimed in claim 1, characterised in that the solvent for said solution of the active substance is chosen from the group comprising water, chloroform, acetone, dichloroethane and ethyl  
35 alcohol.
3. A method as claimed in claim 1, characterised in that, when the active substance is griseofulvine and the solvent is chloroform or acetone, the active substance concentration in said solution is between 2 and 40 g/l.
- 40 4. A method as claimed in claim 1, characterised in that the quantity of said microporous support added to said solution is between 3 and 500 grams per litre of solution.

#### Revendications

#### 45 Revendications pour les Etats contractants suivants : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

- 50 1. Compositions pharmaceutiques à effet retard comprenant un support microporeux contenant la substance active sous forme incorporée, dans lesquelles ledit support microporeux est choisi dans le groupe de substances comprenant la silice, des silicates, des zéolites, l'alumine, le charbon actif et des substances polymères microporeuses ayant des pores d'un diamètre moyen compris entre 5 et 150 nm, une surface spécifique comprise entre 30 et 600 m<sup>2</sup>/g et un diamètre de particule inférieur à 200 micromètres, caractérisées par le fait que ladite substance active est répartie à l'intérieur des pores du support sous forme cristalline, avec un point de fusion inférieur à celui du médicament initial.
- 55 2. Compositions telles que revendiquées dans la revendication 1, caractérisées par le fait que la teneur en ladite substance active peut être comprise entre 4 et 60 % en poids.
3. Compositions telles que revendiquées dans la revendication 1, caractérisées par le fait que ladite

substance active est le diazépán, la digoxine, la griséofulvine, l'acétate de méthylhydroxyprogestérone, la nifédipine, l'acétate de mégestrol, l'halopéridol, la nicardipine, le diltiazem ou l'étoposide.

4. Procédé de préparation de compositions pharmaceutiques à effet retard, comprenant un support microporeux contenant la substance active sous forme incorporée, dans lequel ledit support microporeux est choisi dans le groupe de substances comprenant la silice, des silicates, des zéolites, l'alumine, le charbon actif et des substances polymères microporeuses ayant des pores d'un diamètre moyen compris entre 5 et 150 nm, une surface spécifique comprise entre 30 et 600 m<sup>2</sup>/g et un diamètre de particules inférieur à 200 micromètres, et ladite substance active est choisie dans le groupe comprenant le diazépán, la digoxine, la griséofulvine, l'acétate de méthylhydroxyprogestérone, la nifédipine, l'acétate de mégestrol, l'halopéridol, la nicardipine, le diltiazem et l'étoposide, caractérisé par le fait que l'on ajoute ledit support microporeux à une solution de la substance active, que l'on agite à température ambiante pendant 90 à 100 heures, puis que l'on fait lentement évaporer le solvant à une température de 10 à 20° C en dessous du point d'ébullition de la solution, et à une pression comprise entre 500 et 760 mmHg (66.500-101.000 pa).
5. Procédé tel que revendiqué dans la revendication 4, caractérisé par le fait que le solvant de ladite solution de la substance active est choisi dans le groupe comprenant l'eau, le chloroforme, l'acétone, le dichloroéthane et l'alcool éthylique.
6. Procédé tel que revendiqué dans la revendication 4, caractérisé par le fait que, lorsque la substance active est la griséofulvine et le solvant est le chloroforme ou l'acétone, la concentration de la substance active dans ladite solution se situe entre 2 et 40 g/l.
7. Procédé tel que revendiqué dans la revendication 4, caractérisé par le fait que la quantité dudit support microporeux ajoutée à ladite solution se situe entre 3 et 500 g par litre de solution.
8. Utilisation de compositions pharmaceutiques telles que revendiquées dans la revendication 1, en vue de la préparation de capsules, de comprimés, de pellicules transdermiques, de formes pharmaceutiques à usage topique et dans des suppositoires.

#### Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de préparation de compositions pharmaceutiques à effet retard, comprenant un support microporeux contenant la substance active sous forme incorporée, dans lequel ledit support microporeux est choisi dans le groupe de substances comprenant la silice, des silicates, des zéolites, l'alumine, le charbon actif et des substances polymères microporeuses ayant des pores d'un diamètre moyen compris entre 5 et 150 nm, une surface spécifique comprise entre 30 et 600 m<sup>2</sup>/g et un diamètre de particules inférieur à 200 micromètres, et ladite substance active est choisie dans le groupe comprenant le diazépán, la digoxine, la griséofulvine, l'acétate de méthylhydroxyprogestérone, la nifédipine, l'acétate de mégestrol, l'halopéridol, la nicardipine, le diltiazem et l'étoposide, caractérisé par le fait que l'on ajoute ledit support microporeux à une solution de la substance active, que l'on agite à température ambiante pendant 90 à 100 heures, puis que l'on fait lentement évaporer le solvant à une température de 10 à 20° C en dessous du point d'ébullition de la solution, et à une pression comprise entre 500 et 760 mmHg (66.500-101.000 pa).
2. Procédé tel que revendiqué dans la revendication 1, caractérisé par le fait que le solvant de ladite solution de la substance active est choisi dans le groupe comprenant l'eau, le chloroforme, l'acétone, le dichloroéthane et l'alcool éthylique.
3. Procédé tel que revendiqué dans la revendication 1, caractérisé par le fait que, lorsque la substance active est la griséofulvine et le solvant est le chloroforme ou l'acétone, la concentration de la substance active dans ladite solution se situe entre 2 et 40 g/l.
4. Procédé tel que revendiqué dans la revendication 1, caractérisé par le fait que la quantité dudit support microporeux ajoutée à ladite solution se situe entre 3 et 500 g par litre de solution.

#### Patentansprüche



**Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE**

1. Pharmazeutische Zusammensetzungen mit verlängerter Wirkung welche einen mikroporösen die aktive Substanz in eingebauten Form enthaltenden Träger umfassen, in welchem der besagte mikroporöse Träger aus den Gruppen ausgewählt ist die Kieselsäure, Silikate, Zeolite, Alumina, Aktivkohle und mikroporöse polymerische Substanzen welche Poren von einem mittleren Durchschnitt zwischen 5 und 150 nm, eine spezifische Oberfläche zwischen 30 und 600 m<sup>2</sup>/g und einen mittleren Teilchen Durchmesser von weniger als 200 Mikrometer aufweisen umfasst, dadurch gekennzeichnet, dass die besagte aktive Substanz in den Träger Poren in kristallinen Form mit einem niedrigeren Schmelzpunkt als der Schmelzpunkt der ursprünglichen Substanz verteilt ist.
2. Zusammensetzungen gemäss Anspruch 1, dadurch gekennzeichnet, dass der Inhalt der aktiven Substanz zwischen 4 und 60 Gew. % ist.
3. Zusammensetzungen gemäss Anspruch 1, dadurch gekennzeichnet, dass die besagte aktive Substanz Diazepan, Digoxin, Griseofulvin, Methylhydroxyprogesteron-Azetat, Nifedipin, Megestrolazetat, Haloperidol, Nicardipin, Diltiazem oder Etoposid ist.
4. Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen mit verlängerten Wirkung welche einen mikroporösen die aktive Substanz in eingebauten Form enthaltenden Träger umfassen, in welchen der besagte mikroporöse Träger aus den Gruppen ausgewählt ist die Kieselsäure, Silikate, Zeolite, Alumina, Aktivkohle und mikroporöse polymerische Substanzen welche Poren von einem mittleren Durchschnitt zwischen 5 und 150 nm, eine spezifische Oberfläche zwischen 30 und 600 m<sup>2</sup>/g und einen mittleren Teilchen Durchmesser von weniger als 200 Mikrometer aufweisen umfasst, und die aktive Substanz aus den Diazepan, Digoxin, Griseofulvin, Methylhydroxyprogesteron-Azetat, Nifedipin, Megestrolazetat, Haloperidol, Nicardipin, Diltiazem oder Etoposid umfassenden Gruppen ausgewählt ist, dadurch gekennzeichnet, dass der besagte mikroporöse Träger zu einer Lösung der aktiven Substanz zugegeben ist, die Lösung 90-100 Stunden bei Zimmertemperatur gerührt wird, der Lösungsmittel bei einer Temperatur welche 10 bis 20 °C niedriger als der Lösungskochpunkt ist und bei einem Druck zwischen 500 und 760 mmHg (66.500-101.000 pa) eingedämpft wird.
5. Verfahren gemäss Anspruch 4, dadurch gekennzeichnet, dass der Lösungsmittel für die besagte Lösung der aktiven Substanz aus der Wasser, Chloroform, Azeton, Dichloräthan und Äthylalkohol enthaltenden Gruppe ausgewählt wird.
6. Verfahren gemäss Anspruch 4, dadurch gekennzeichnet, dass die aktive Substanz Griseofulvin und der Lösungsmittel Chloroform oder Azeton ist, die Konzentration der aktiven Substanz zwischen 2 und 40 g/l ist.
7. Verfahren gemäss Anspruch 4, dadurch gekennzeichnet, dass die Menge der zur besagten Lösung zugegebenen mikroporösen Träger zwischen 3 und 500 g/l ist.
8. Verwendung der pharmazeutischen Zusammensetzungen gemäss Anspruch 1, zur Herstellung von Kapseln, Tabletten, Pflastern, pharmazeutischen Formen zur topischen Anwendung und Suppositorien.

**Patentansprüche für folgende Vertragsstaaten : ES, GR**

1. Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen mit verlängerter Wirkung welche einen mikroporösen die aktiven Substanz in eingebauten Form enthaltenden Träger umfassen, in welchen der besagte mikroporöse Träger aus den Gruppen ausgewählt ist die Kieselsäure, Silikate, Zeolite, Alumina, Aktivkohle und mikroporöse polymerische Substanzen welche Poren von einem mittleren Durchschnitt zwischen 5 und 150 nm, eine spezifische Oberfläche zwischen 30 und 600 m<sup>2</sup>/g und einen mittleren Teilchen Durchmesser von weniger als 200 Mikrometer aufweisen umfasst, und die aktive Substanz aus den Diazepan, Digoxin, Griseofulvin, Methylhydroxyprogesteron-Azetat, Nifedipin, Megestrolazetat, Haloperidol, Nicardipin, Diltiazem oder Etoposid umfassenden Gruppen ausgewählt ist, dadurch gekennzeichnet, dass der besagte mikroporöse Träger zu einer Lösung der aktiven Substanz zugegeben ist, die Lösung 90-100 Stunden bei Zimmertemperatur gerührt wird, der Lösungsmittel bei einer Temperatur welche 10 bis 20 °C niedriger als der Lösungskochpunkt ist und bei einem Druck

## EP 0 336 014 B1

zwischen 500 und 760 mmHg (66.500-101.000 pa) eingedämpft wird.

2. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass der Lösungsmittel für die besagte Lösung der aktiven Substanz aus der Wasser, Chloroform, Azeton, Dichloräthan und Äthylalkohol  
5 enthaltenden Gruppe ausgewählt wird.

3. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass die aktive Substanz Griseofulvin und der Lösungsmittel Chloroform oder Azeton ist, die Konzentration der aktiven Substanz zwischen 2 und 40  
10 g/l ist.

4. Verfahren gemäss Anspruch 1, dadurch gekennzeichnet, dass die Menge der zur besagten Lösung zugegebenen mikroporösen Träger zwischen 3 und 500 g/l ist.

15

20

25

30

35

40

45

50

55